BioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edge

Ayisha Sharma

News Reporter

BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to investigate the asset in combination …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edge

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Rare disease biopharma companies weigh in on FDA's new innovation hub

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

BioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edge